Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
58 participants
INTERVENTIONAL
2015-01-31
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Randomization Randomization was performed using the website www.randomization.com. The allocation sequence remained concealed throughout the study. Researchers, outcome assessors and patients were blinded to the treatment received.
The trial was registered at www.clinicaltrials.gov. (number NCT02764047)
Intervention Patients receive the probiotic or placebo supplement in identical medicine bottles to maintain blinding. The instruction for administration of the capsules is taking 1 capsule per day before bedtime with 1 cup of water. Patients are also advised to keep medications in use without change until the end of the study and to communicate the investigators if they used antibiotics.
Questionary - Profile and the risk factors for fibrosis and NASH The profile of patients with NASH will be analyzed according to the variables collected (age, gender, smoking, diabetes, hypertension, high blood pressure, heart rate, weight, height, BMI, waist circumference, AST, ALT, total bilirubin, albumin, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, insulin, C-reactive protein, platelets), as well as the possible risk factors for the development of the disease. It is believed that the interaction between diet, intestinal microbiota and genetic background is the most important in the development and progression of NAFLD.
Participants are requested to bring all medication they use or a list from their pharmacists to the research center. During a medication interview generic name, dose and frequency are registered by trained staff.
Nutritional and Physical assessment Height is measured at baseline to confirm BMI. At 0 (baseline), 3 and 6 months body weight is measured using a calibrated balance, waist circumference, systolic blood pressure, diastolic blood pressure, heart rate. Body composition is assessed at baseline and 6 months phase angle of bioelectrical impedance analysis (BIA) method, hand grip strength.
Biopsy, Fibromax and NAFLD score Improvement in liver injury will be defined by reduction of fibrosis, steatosis and inflammation in liver biopsy and noninvasive tests Fibromax test and NAFLD score of varying degrees. NAFLD score and the FibroMax ™ test (Biopredictive, Paris, France), which evaluates fibrosis, inflammation and hepatic steatosis. Sensitivity, specificity, positive and negative predictive values will be assessed for comparison of these non-invasive fibrosis assessment methods with liver biopsy. Hepatic transaminases (AST, ALT) will be assessed as well.
Biochemical markers - General labs and Cytokines sample At baseline, 3 and 6 months, a fasting blood sample is taken for measurement of plasma laboratory tests (AST, ALT, total bilirubin, albumin, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, insulin, C-reactive protein, platelet), serum -1 leptin and MCP will be quantified. To determine levels of serum leptin and MCP-1, 15 mL venous blood samples were taken from the antecubital vein, and transferred to tubes without anticoagulant (4 mL). Blood samples were collected between 9:00 a.m. and 11:00 a.m., at baseline (PRE), after 3 months and after 6 months. Tubes without anticoagulant were centrifuged at 1048g for 10 min. Serum samples were then divided into several aliquots and stored at -20 °C for further analysis. Serum leptin and MCP-1 levels were determined using the enzyme-linked immunosorbent assay (ELISA) method, using the specific kit (Peprotech, EUA) following the manufacturer's instructions. All samples were measured in duplicate by microplate reader SpectraMax M2e (Molecular Devices, EUA). Intra-assay coefficients of variation were always \<5.0%, 3.8% for BDNF and cortisol, respectively.
Gut microbiota - Stool sample Fecal samples are collected by patients in their own bottle and delivered to the Nutrition Clinic in Hepatology Hospital Santa Clara Santa Casa Hospital Complex. The samples are transported to the Immunology Laboratory. Samples are aliquoted in 4 samples, frozen, and stored in -20 and -80 degrees freezers. At the end of the collections, DNA will be extracted (MoBio PowerFecal® DNA Isolation Kit). DNA samples will be sent to the University Institute Research Center of Cardiology and Pneumology at the University of Quebec Laval. Genetic sequencing of the microflora in the samples will be performed. Results will be analyzed and correlated with clinical outcomes.
Food record Eligible patients will be submitted to food assessment using a food frequency questionnaire validated for liver diseases, and a 24-hour recall survey used for possible comparisons with the food frequency questionnaire. The multiple-step method for performing is applied during the patient interview, aiming to improve collection accuracy and reduce memory bias.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo capsule
Probiotic
L. acidophilus 10⁹, B. lactis 10⁹
Probiotic
Probiotic capsule
Probiotic
L. acidophilus 10⁹, B. lactis 10⁹
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic
L. acidophilus 10⁹, B. lactis 10⁹
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Irmandade Santa Casa de Misericórdia de Porto Alegre
OTHER
Federal University of Health Science of Porto Alegre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gabriela Zanatta Port
Master
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cristiane V Tovo, PHD
Role: PRINCIPAL_INVESTIGATOR
FUHSPA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Irmandade Santa Casa de Misericórdia
Porto Alegre, Rio Grande do Sul, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011 Sep;15(9):1090-5.
Escouto GS, Port GZ, Tovo CV, Fernandes SA, Peres A, Dorneles GP, Houde VP, Varin TV, Pilon G, Marette A, Buss C. Probiotic Supplementation, Hepatic Fibrosis, and the Microbiota Profile in Patients with Nonalcoholic Steatohepatitis: A Randomized Controlled Trial. J Nutr. 2023 Jul;153(7):1984-1993. doi: 10.1016/j.tjnut.2023.05.019. Epub 2023 May 22.
Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013 Oct 28;19(40):6911-8. doi: 10.3748/wjg.v19.i40.6911.
Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005 Jul;39(6):540-3. doi: 10.1097/01.mcg.0000165671.25272.0f.
Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013 Mar-Apr;12(2):256-62.
Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial. Int J Prev Med. 2013 May;4(5):531-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
852.771
Identifier Type: -
Identifier Source: org_study_id